Navigation Links
HIV -- Geneticists map human resistance to AIDS
Date:10/28/2013

The key to future HIV treatment could be hidden right in our own genes. Everyone who becomes infected deploys defense strategies, and some even manage to hold the virus at bay without any therapy at all. This immune system struggle leaves its mark within the pathogen itself genetic mutations that indicate how the virus reacted to its host's attacks. Scientists from EPFL and the Vaud university hospital center (UNIL-CHUV) retraced the entire chain of events in these battles, from the genome of the virus to the genome of the victim. They have created the first map of human HIV resistance. The goal of their research, which has been published in the journal eLife on the 29th of October, is to find new therapeutic targets and to enable individualized treatment strategies.

The human immune system is constantly developing strategies to fight HIV. Unfortunately, "the genome of the virus also changes rapidly, at a rate of millions of mutations a day," explains Jacques Fellay, co-author and EPFL researcher. In the majority of cases, the pathogen finds an effective strategy via this natural selection.

Sometimes the virus is faced with a tougher opponent. It resists, but its ability to replicate is compromised. "The virus survives but replicates more slowly, and thus its capacity for destruction is in some sense neutralized," says the scientist.

By studying strains of HIV that have been living in human hosts, the researchers can identify specific genetic mutations. These are like scars that each bear witness to a very specific attack launched by the immune system. What are the human genes involved in these defense strategies? And which, among all our genetic variations, predispose us to increased HIV resistance or, on the contrary, increased vulnerability? The scientists developed a method that allowed them to find answers to these questions.

A supercomputer, 1,071 patients and millions of combinations

To draw up the first map of human HIV resistance, the researchers had to analyze an enormous amount of data. They studied various strains of HIV from 1,071 seropositive individuals. They crossed more than 3,000 potential mutations in the viral genome with more than 6 million variations in the patients' genomes. Using supercomputers, they studied all these possible combinations and identified correspondence between patients.

"We had to study the virus before the patient had undergone treatment, which is far from easy," says Fellay. This meant they had to search in data banks established in the 1980s, before effective therapies were made available.

This novel, indirect method made it possible to obtain the most complete global overview to date of human genes and their implications in terms of HIV resistance. It allows us to not only better understand how we defend ourselves from attack but also how the virus adapts itself to our defense mechanisms. "We now have a true database that tells us which human genetic variation will induce which kind of mutation in the virus", explains Amalio Telenti, co-author and UNIL-CHUV researcher.

Therapies inspired by our own natural defense

This research has two major implications. New therapies could be developed based on studying humans' natural defenses, particularly those that result in a reduced replication of the virus. In addition, the scientists hope that by profiling the genome of HIV-infected individuals, it will be possible to develop individually targeted treatments that take into account the patients' genetic strengths and weaknesses.


'/>"/>

Contact: Jacques Fellay
jacques.fellay@epfl.ch
41-799-481-129
Ecole Polytechnique Fdrale de Lausanne
Source:Eurekalert

Related biology news :

1. CSHL geneticists solve mystery of EEC Syndromes variable severity in children
2. Study maps human impacts on top ocean predators along US west coast
3. Induced pluripotent stem cells reveal differences between humans and great apes
4. Rats! Humans and rodents process their mistakes
5. Baculovirus-recognizing human cell receptor identified for the first time
6. New approach to treating human brain cancer could lead to improved outcomes
7. Superconductivity to meet humanitys greatest challenges
8. Functional genetic variation in humans: Comprehensive map published
9. DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research
10. Better sharing of genetic information in human health
11. Novel avian influenza A virus has potential for both virulence and transmissibility in humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December 15, 2016 ... financial services provider, today announced an agreement with NuData Security, ... to join forces. The partnership will enable clients to focus ... compliance with local data protection regulation. ... In order to provide a ...
(Date:12/15/2016)... DUBLIN , Dec 15, 2016 ... Research and Markets has announced ... to their offering. The report forecasts the global military ... 2016-2020. The report has been prepared based on an ... market landscape and its growth prospects over the coming years. The report ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... , Jan. 23, 2017  Alkahest Inc. ... treatments for neurodegenerative diseases and other age-related conditions, ... the company as Chief Medical Officer. In this ... clinical development activities at Alkahest and serve on ... most recently served as Executive Director at Dynavax, ...
(Date:1/23/2017)... ... January 23, 2017 , ... CallTower is proud to announce ... of the Year Award winner for 2017. , For three consecutive years, CallTower ... In 2016, CallTower was awarded with the hosted VoIP Excellence award and in 2015, ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and Transonic Systems Inc. ... will receive exclusive marketing and sales rights for all non-OEM Transonic products in Japan. ... in Japan, the new Nipro - Transonic JV is a natural next step to ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
Breaking Biology Technology: